Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 14/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 8/20 | 0.48 |
| ▸ | PARP3 | Q9Y6F1 | 8/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3962929 | 0.82 | PARP1 (0.45) | PARP1PARP2PARP3ADORA3NOTUM | |
| SCHEMBL3965779 | 0.79 | PARP1 (0.44) | PARP1PARP2PARP3ADORA3NOTUM | |
| SCHEMBL27730703 | 0.78 | PARP1 (0.54) | PARP1PARP2PARP3ADORA3 | |
| SCHEMBL5904741 | 0.77 | NOTUM (0.42) | ADORA3NOTUMSRCBRAFKDR | |
| SCHEMBL3968503 | 0.76 | NOTUM (0.43) | PARP1PARP2PARP3ADORA3NOTUM | |
| SCHEMBL3963596 | 0.76 | PARP1 (0.57) | PARP1PARP2PARP3ADORA3 | |
| SCHEMBL5708210 | 0.76 | PARP1 (0.47) | PARP1PARP2PARP3ADORA3 | |
| SCHEMBL3968483 | 0.76 | ADORA3 (0.43) | PARP1PARP2PARP3ADORA3NOTUM | |
| SCHEMBL3963382 | 0.74 | ADORA3 (0.47) | PARP1PARP2PARP3ADORA3 | |
| SCHEMBL5904618 | 0.74 | NOTUM (0.40) | ADORA3NOTUMSRCBRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| EP-1706386-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005066136-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | PPARD, PPARA, PPARG | PARP1 3140/4885PARP2 3359/4885PARP3 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.